Skip to main content
SpringerLink
Log in

Abuse Potential of Nicotine Replacement Therapies

  • Adverse Effects
  • Abuse Potential of Nicotine Replacement Therapies
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Summary

The abuse liability of nicotine replacement therapies is an important clinical consideration in the pharmacological treatment of nicotine dependence associated with cigarette smoking.

Abuse liability is defined as: (i) the likelihood oftaking a substance repeatedly, taking into account both factors that are likely to increase use (e.g. faster onset of pharmacodynamic effect) and factors that are likely to decrease use (e.g. adverse effects); and (ii) the likelihood of adverse consequences (both long and short term).

It can be concluded that most of the nicotine replacement therapies have lower abuse liability than tobacco cigarettes. Among the alternative therapies available, it would appear that those with a slower onset (e.g. chewing gum and transdermal systems) are less likely to be abused than those with a faster onset.

Experience with existing nicotine replacement therapies may be useful for future research into the development of new therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Benowitz N. Pharmacologic aspects of cigarette smoking and nicotine addiction. N Engl J Med 1988; 319: 1318–30

    Article  PubMed  CAS  Google Scholar 

  2. Stolerman IP, Jarvis MJ. The scientific case that nicotine is addictive. Psychopharmacology 1995; 117: 2–10

    Article  PubMed  CAS  Google Scholar 

  3. Hughes J. Risk-benefit assessment of nicotine preparations in smoking cessation. Drug Saf 1993; 8: 49–56

    Article  PubMed  CAS  Google Scholar 

  4. Busto U, Sellers E. Pharmacokinetic detenninants of drug abuse and dependence. C1in Pharmacokinet 1986; 11: 144–53

    Article  CAS  Google Scholar 

  5. de Wit H, Dudish S, Ambre J. Subjective and behavioral effects of diazepam depend on its rate of onset. Psychopharmacology 1993; 112: 324–30

    Article  PubMed  Google Scholar 

  6. Henningfield J, Keenan R. Nicotine delivery kinetics and abuse liability. J Consult C1in Psychol 1993; 61: 1–8

    Google Scholar 

  7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

    Google Scholar 

  8. Jasinski DR. History of abuse liability testing in humans. Br J Addict 1991; 86: 1559–62

    Article  PubMed  CAS  Google Scholar 

  9. McNair D, Lorr M, Droppleman L. Profile of mood states [manual]. San Diego: Educational and Industrial Testing Service, 1971

    Google Scholar 

  10. Martin W, Sloan J, Sapira J, et al. Physiological, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther 1971; 12: 245–58

    PubMed  CAS  Google Scholar 

  11. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 1980; 10: 189–209

    Article  PubMed  CAS  Google Scholar 

  12. Foltin RW, Evans SM. Performance effects of drugs of abuse. Hum Psychopharmacol 1993; 8: 9–19

    Article  Google Scholar 

  13. Henningfield J, Goldberg S. Cigarette smokers self-administer intravenous nicotine. Pharmacol Biochem Behav 1983; 19: 887–90

    Article  PubMed  CAS  Google Scholar 

  14. Pomerleau C, Pomerleau O. Euphoriant effects of nicotine in smokers. Psychopharmacology 1992; 108: 460–5

    Article  PubMed  CAS  Google Scholar 

  15. Foltin R, Fischman M. Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend 1991; 28: 3–48

    Article  PubMed  CAS  Google Scholar 

  16. de Wit H, Griffiths RR. Testing the abuse liability of anxiolytic and hypnotic drugs in humans. Drug Alcohol Depend 1991; 28: 83–111

    Article  PubMed  Google Scholar 

  17. Benowitz N, Jacob P, Savanapridi C. Determinants of nicotine intake while chewing nicotine polacri1ex gum. CIin Pharmacol Ther 1987; 41: 467–73

    Article  CAS  Google Scholar 

  18. Svensson CK. Clinical pharmacokinetics of nicotine. Clin Pharmacokinet 1987; 12: 30–40

    Article  PubMed  CAS  Google Scholar 

  19. Benowitz N, Porchet H, Sheiner L, et al. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. CIin Pharmacol Ther 1988; 44 (1): 23–8

    Article  CAS  Google Scholar 

  20. Sutherland G, Russell M, Stapleton J, et al. Nasal nicotine spray: a rapid nicotine delivery system. Psychopharmacology 1992; 108: 512–8

    Article  PubMed  CAS  Google Scholar 

  21. Jarvis M, Raw M, Russell M, et al. Randomized control trial of nicotine chewing gum. BMJ 1982; 285: 537–40

    Article  PubMed  CAS  Google Scholar 

  22. Hughes J, Hatsukami D, Pickens R, et al. Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology 1984; 83: 82–7

    Article  PubMed  CAS  Google Scholar 

  23. Schneider N, Jarvik M, Forsythe A. Nicotine vs. placebo gum in the alleviation of withdrawal during smoking cessation. Addict Behav 1984; 9: 149–56

    Article  PubMed  CAS  Google Scholar 

  24. West R, Jarvis M, Russell M, et al. Effect of nicotine replacement on the cigarette withdrawal syndrome. Br J Addict 1984; 79: 215–9

    PubMed  CAS  Google Scholar 

  25. Heishman S, Snyder F, Henningfield J. Performance, subjective, and physiological effects of nicotine in non-smokers. Drug Alcohol Depend 1993; 34: 11–8

    Article  PubMed  CAS  Google Scholar 

  26. Haertzen C. Development of scales based on patterns of drug effects using the Addiction Research Center Inventory (ARCI). Psycho I Rep 1966; 18: 163–94

    Article  CAS  Google Scholar 

  27. Jasinski D, Martin W, Sapira J. Antagonism of the subjective, behavioral, pupillary, and respiratory depressant effects of cyclazocine by naloxone. Clin Pharmacol Ther 1968; 9: 215–22

    PubMed  CAS  Google Scholar 

  28. Coslett-Nemeth R, Benowitz N, Robinson N, et al. Nicotine gum: chew rate, subjective effects and plasma nicotine. Pharmacol Biochem Behav 1988; 29: 747–51

    Article  Google Scholar 

  29. Pickworth W, Heming R, Henningfield J. Electroencephalographic effects of nicotine chewing gum in humans. Pharmacol Biochem Behav 1986; 25: 879–82

    Article  PubMed  CAS  Google Scholar 

  30. Wewers M, Tejwani G, Anderson J. Plasma nicotine, plasma beta-endorphin and mood states during periods of chronic smoking, abstinence and nicotine replacement. Psychopharmacology 1994; 116: 98–102

    Article  PubMed  CAS  Google Scholar 

  31. Shiffman S, Jarvik M. Smoking withdrawal. Symptoms in two weeks of abstinence. Psychopharmacology 1976; 50: 35–9

    Article  PubMed  CAS  Google Scholar 

  32. Gross J, Stitzer M. Nicotine replacement: ten-week effects on tobacco withdrawal symptoms. Psychopharmacology 1989; 98: 334–41

    Article  PubMed  CAS  Google Scholar 

  33. West R, Schneider N. Craving for cigarettes. Br J Addict 1985; 82: 407–15

    Article  Google Scholar 

  34. Hughes J, Gust S, Keenan R, et al. Long-term use of nicotine vs placebo gum. Arch Intern Med 1991; 151: 1993–8

    Article  PubMed  CAS  Google Scholar 

  35. Hughes J, Strickler G, King D, et al. Smoking history, instructions and the effects of nicotine: two pilot studies. Pharmacol Biochem Behav 1989; 34: 149–55

    Article  PubMed  CAS  Google Scholar 

  36. Hughes J, Pickens R, Spring W, et al. Instructions control whether nicotine will serve as a reinforcer. J Pharmacol Exp Ther 1985; 235: 106–12

    PubMed  CAS  Google Scholar 

  37. Hughes J, Gulliver S, Amoria G, et al. Effect of instructions and nicotine on smoking cessation, withdrawal symptoms and selfadministration of nicotine gum. Psychopharmacology 1989; 99: 486–91

    Article  PubMed  CAS  Google Scholar 

  38. Sherwood N. Effects of nicotine on human psychomotor performance. Hum Psychopharmacol 1993; 8: 155–84

    Article  CAS  Google Scholar 

  39. Hughes J, Gust S, Keenan R, et al. Nicotine vs placebo gum in general medical practice. JAMA 1989; 261: 1300–5

    Article  PubMed  CAS  Google Scholar 

  40. Hughes J, Miller S. Nicotine gum to help stop smoking. JAMA 1984; 252: 2855–8

    Article  PubMed  CAS  Google Scholar 

  41. Schneider N, Jarvik M, Forsythe A, et al. Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial. Addict Beh 1983; 8: 253–61

    Article  CAS  Google Scholar 

  42. Hughes J. Long term use of nicotine replacement therapy. In: Henningfield J, Stitzer M, editors. New developments in nicotine delivery systems: proceedings of a conference; 1990 Sept 24: Johns Hopkins University. Ossining (NY): Cortlandt Communications, 1991

    Google Scholar 

  43. Palmer KJ, Buckley MM, Faulds D. Transdermal nicotine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs 1992; 44: 498–529

    Article  PubMed  CAS  Google Scholar 

  44. Benowitz N, Jacob P, Olsson P, et al. Intravenous nicotine retards transdermal absorption of nicotine: evidence of blood flow-limited percutaneous absorption. Clin Pharmacol Ther 1992; 52: 223–30

    Article  PubMed  CAS  Google Scholar 

  45. Bannon Y, Corish J, Corrigan O, et al. Transdermal delivery of nicotine in normal human volunteers: a single dose and multiple dose study. Eur J Clin Pharmacol 1989; 37: 285–90

    Article  PubMed  CAS  Google Scholar 

  46. Gupta S, Benowitz N, Jacob P, et al. Bioavailability and absorption kinetics of nicotine following application of a transdermal system. Br J CIin Pharmacol 1993; 36: 221–7

    Article  CAS  Google Scholar 

  47. Dubois J, Sioufi A, Muller P, et al. Pharmacokinetics and bioavailability of nicotine in healthy volunteers following single and repeated administration of different doses of transdermal nicotine systems. Methods Find Exp Clin Pharmacol 1989; 11: 187–95

    PubMed  CAS  Google Scholar 

  48. Caspary S, Keller-Stanislawski B, Huber T, et al. Pharmacokinetics of nicotine after application of a 30 cm2 nicotine patch under steady-state conditions. Int J CIin Psychopharmacol 1991; 29: 92–5

    CAS  Google Scholar 

  49. Kochak G, Sun J, Choi R, et al. Pharmacokinetic disposition of multiple-dose transdermal nicotine in healthy adult smokers. Pharm Res 1992; 9: 1451–5

    Article  PubMed  CAS  Google Scholar 

  50. Srivastava E, Russell M, Feyerabend C, et al. Sensitivity and tolerance to nicotine in smokers and nonsmokers. Psychopharmacology 1991; 105: 63–8

    Article  PubMed  CAS  Google Scholar 

  51. Daughton D, Heatley S, Prendergast J. Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy — a randomized double-blind placebo-controlled trial. Mayo Clin Proc 1991; 65: 1529–37

    Google Scholar 

  52. Tonnesen P, Norregaard J, Simonsen K, et al. A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med 1991; 325: 311–5

    Article  PubMed  CAS  Google Scholar 

  53. Hurt R, Dale L, Offord K, et al. Serum nicotine and cotinine levels during nicotine-patch therapy. Clin Pharmacol Ther 1993; 54: 98–106

    Article  PubMed  CAS  Google Scholar 

  54. Rose J, Levin E, Behm F, et al. Transdermal nicotine facilitates smoking cessation. Clin Pharmacol Ther 1990; 47: 323–30

    Article  PubMed  CAS  Google Scholar 

  55. Group TNS. Transderrnal nicotine for smoking cessation: sixmonth results from two multicenter controlled clinical trials. JAMA 1991; 266: 3133–8

    Article  Google Scholar 

  56. Group ICRFGPR. Effectiveness of a nicotine patch in helping people to stop smoking: results of a randomized trial in general practice. BMJ 1993; 306: 1304–8

    Article  Google Scholar 

  57. Russell M, Stapleton J, Feyerabend C, et al. Targeting heavy smokers in general practice: randomized controlled trial of transderrnal nicotine patches. BMJ 1993; 306: 1308–12

    Article  PubMed  CAS  Google Scholar 

  58. Fagerstrom K, Schneider N, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology 1993; 111: 271–7

    Article  PubMed  CAS  Google Scholar 

  59. Abelin T, Ehrsam R, Buhler-Reichert A, et al. Effectiveness of a transdermal nicotine system in smoking cessation studies. Methods Find Exp Clin Pharmacol 1989; 11: 205–14

    PubMed  CAS  Google Scholar 

  60. Muller P, Abelin T, Ehrsam R, et al. The use of transdermal nicotine in smoking cessation. Lung Supp 1990; 1: 445–3

    Article  Google Scholar 

  61. Levin E, Westman E, Stein R, et al. Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking. J Clin Psychopharmacol 1994; 14: 41–9

    Article  PubMed  CAS  Google Scholar 

  62. Bunker E, Pickworth W, Henningfield J. Nicotine patch: effect on spontaneous smoking. In: Harris L, editor. National Institute on Drug Abuse research monograph series 119, problems of drug dependence 1991. Rockville (MD): USPHS, 1992

    Google Scholar 

  63. Pickworth WB, Butschky MF, Henningfield JE. A nicotine patch reduces subjective and objective measures of tobacco withdrawal. In: Harris L, editor. National Institute on Drug Abuse research monograph series 153. Rockville (MD): USPHS, 1995: 194

    Google Scholar 

  64. Schneider N. Nicotine therapy in smoking cessation: pharrnacokinetic considerations. Clin Pharmacokinet 1992; 23: 169–72

    Article  PubMed  CAS  Google Scholar 

  65. Henningfield J, London E, Benowitz N. Arterial-venous differences in plasma concentrations of nicotine after cigarette smoking. JAMA 1990; 263: 2049–50

    Article  PubMed  CAS  Google Scholar 

  66. Jaffe J. Drug addiction and drug abuse. In: Gilman A, Raul T, Nies A, et al., editors. The pharmacological basis oftherapeutics. New York: Pergamon Press, 1990: 522–73

    Google Scholar 

  67. Perkins KA, Sexton J, Reynolds W, et al. Comparison of acute subjective and heart rate effects of nicotine intake via tobacco smoking versus nasal spray. Pharmacol Biochem Behav 1994; 47: 295–9

    Article  PubMed  CAS  Google Scholar 

  68. Hjalmarson A, Franzon M, Westin A, et al. Effect of nicotine nasal spray on smoking cessation. Arch Intern Med 1994; 154: 2567–72

    Article  PubMed  CAS  Google Scholar 

  69. Belcher M, Jarvis M, Sutherland G. Nicotine absorption and dependence in an over the counter aid to stopping smoking. BMJ 1989; 298: 570

    Article  PubMed  CAS  Google Scholar 

  70. Hasenfratz M, Battig K. Nicotine absorption and the subjective and physiologic effects of nicotine toothpicks. Clin Pharmacol Ther 1991; 50: 456–61

    Article  PubMed  CAS  Google Scholar 

  71. Jarvis M, Hajek P, Russell M, et al. Nasal nicotine solution as an aid to cigarette withdrawal: a pilot clinical trial. Br J Addict 1987; 82: 983–8

    Article  PubMed  CAS  Google Scholar 

  72. Burch S, Erbland M, Gann L, et al. Plasma nicotine levels after inhalation of aerosolized nicotine. Am Rev Respir Dis 1989; 140: 955–7

    PubMed  CAS  Google Scholar 

  73. Leischow SJ. The nicotine vaporizer. Health Values 1994; 18: 4/9/2012

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, The University of Chicago, 5841 S. Maryland Avenue, Chicago, Illinois, 60637, USA

    Harriet de Wit

  2. Departments of Psychiatry and Anesthesia and Critical Care, The University of Chicago, Chicago, Illinois, USA

    James Zacny

Authors
  1. Harriet de Wit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Zacny
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Wit, H., Zacny, J. Abuse Potential of Nicotine Replacement Therapies. CNS Drugs 4, 456–468 (1995). https://doi.org/10.2165/00023210-199504060-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199504060-00008

Keywords

Search

Navigation